Gabapentin
Product Images NDC 21695-058

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 21695-058). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

600mg Package Label (058 Sun)

GABAPENTIN 600 mg tablets label by Rebel Distributors Corp. The label displays the product name, strength, dosage form, and tablet count (#30). It includes the NDC number 21695-058-30 and Product ID PG005830CA. The label is marked as prescription-only and contains manufacturer and storage information, including storage at controlled room temperature and keeping out of reach of children.*

FDA Label Image

800mg Package Label (059 Sun)

Label for Gabapentin 800 mg tablets, count 90, from Physician Partner under Rebel Distributors Corp. The label states each tablet contains 800 mg of Gabapentin. The label includes storage instructions and the product ID PG005990, with the NDC 21865-059-90.*

FDA Label Image

Gabapentin-fig01 (Gabapentin Fig01)

Line graph depicting weekly mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin shows a greater reduction in mean pain scores compared to placebo, with statistically significant differences (p<0.01) marked by asterisks.*

FDA Label Image

Gabapentin-fig02 (Gabapentin Fig02)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks for placebo and gabapentin dosed groups (1800 mg/day and 2400 mg/day). The y-axis is Mean Pain Score (0-10), and the x-axis is Weeks (Baseline to 7). It includes a 3-week dose titration period followed by a 4-week fixed dose period, with the gabapentin groups showing lower mean pain scores than placebo throughout the study.*

FDA Label Image

Gabapentin-fig03 (Gabapentin Fig03)

A bar chart comparing the percentage of responders at endpoint from two controlled PHN studies involving GABAPENTIN (GBP) at doses 1800, 2400, and 3600 mg versus placebo (PBO). The y-axis represents the percentage of responders, showing higher response rates for GBP groups (29%, 32%, 34%) compared to placebo (12%, 14%), with significance levels indicated by asterisks.*

FDA Label Image

Gabapentin-fig04 (Gabapentin Fig04)

This figure is a scatter plot showing the responder rate difference (%) from placebo by daily gabapentin dose (mg) across three studies labeled a, b, and c. The x-axis represents daily doses (600, 900, 1200, 1800 mg), and the y-axis represents percentage difference. Each study is denoted by different square markers indicating response variation by dose in patients aged 12 years or older with partial seizures under adjunctive therapy.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

Chemical structure diagram of gabapentin showing its cyclohexane ring attached to amino and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.